GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Cyclically Adjusted Price-to-FCF

Eli Lilly and Co (Eli Lilly and Co) Cyclically Adjusted Price-to-FCF : 207.21 (As of Apr. 27, 2024)


View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), Eli Lilly and Co's current share price is $733.51. Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $3.54. Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is 207.21.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LLY' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 13.08   Med: 28.05   Max: 221.53
Current: 206.95

During the past years, Eli Lilly and Co's highest Cyclically Adjusted Price-to-FCF was 221.53. The lowest was 13.08. And the median was 28.05.

LLY's Cyclically Adjusted Price-to-FCF is ranked worse than
92.31% of 325 companies
in the Drug Manufacturers industry
Industry Median: 32.81 vs LLY: 206.95

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Eli Lilly and Co's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $-2.172. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $3.54 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted Price-to-FCF Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.22 44.71 68.58 84.88 164.46

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.88 77.20 109.24 137.06 164.46

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted Price-to-FCF falls into.



Eli Lilly and Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eli Lilly and Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=733.51/3.54
=207.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Eli Lilly and Co's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.172/129.4194*129.4194
=-2.172

Current CPI (Dec. 2023) = 129.4194.

Eli Lilly and Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.065 99.695 0.084
201406 0.742 100.560 0.955
201409 1.256 100.428 1.619
201412 0.630 99.070 0.823
201503 -0.444 99.621 -0.577
201506 0.552 100.684 0.710
201509 0.733 100.392 0.945
201512 0.415 99.792 0.538
201603 -0.351 100.470 -0.452
201606 1.091 101.688 1.389
201609 1.352 101.861 1.718
201612 1.449 101.863 1.841
201703 -0.626 102.862 -0.788
201706 1.352 103.349 1.693
201709 1.357 104.136 1.686
201712 1.198 104.011 1.491
201803 0.191 105.290 0.235
201806 -0.331 106.317 -0.403
201809 1.775 106.507 2.157
201812 0.808 105.998 0.987
201903 -0.091 107.251 -0.110
201906 0.829 108.070 0.993
201909 1.273 108.329 1.521
201912 1.788 108.420 2.134
202003 0.122 108.902 0.145
202006 2.165 108.767 2.576
202009 1.527 109.815 1.800
202012 1.089 109.897 1.282
202103 1.321 111.754 1.530
202106 1.367 114.631 1.543
202109 1.291 115.734 1.444
202112 1.904 117.630 2.095
202203 1.812 121.301 1.933
202206 0.409 125.017 0.423
202209 1.731 125.227 1.789
202212 1.132 125.222 1.170
202303 0.916 127.348 0.931
202306 -0.226 128.729 -0.227
202309 -2.013 129.860 -2.006
202312 -2.172 129.419 -2.172

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (NYSE:LLY) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eli Lilly and Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (Eli Lilly and Co) Business Description

Industry
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017

Eli Lilly and Co (Eli Lilly and Co) Headlines